#ISTH2022

SUPPORTED SYMPOSIA & PRESENTATION THEATERS
ISTH 2022 Supported Symposia & Presentation Theaters
(as of 6/13/22)
The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2022 Congress in London, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis.
See below for session titles.
Live Supported Symposia and Presentation Theaters
Saturday, July 9, 11:30 – 12:45 Supported Symposia
-
AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions (BioMarin Pharmaceutical Inc.)
-
Anticoagulant Advancements for VTE in All Ages and NVAF in Adult Patients (Boehringer Ingelheim)
-
Living with ITP: Thrombotic Risk and Patient’s Perspective (GRIFOLS)
-
A Key Factor: Aiming for All-Round Bleed Protection in Haemophilia A (Octapharma AG)
-
Shining a Light on Severe Congenital Protein C Deficiency (SCPCD) (Takeda Pharmaceutical Company Limited)
Sunday, July 10, 07:00 – 07:45 Supported Symposium
-
Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact? (MedScape/ISTH/Takeda Pharmaceuticals U.S.A, Inc.)
Sunday, July 10, 12:15 – 13:00 Presentation Theaters
-
Achieving Balance with Prophylaxis in Hereditary Factor X Deficiency – Treatment Across the Ages (Bio Products Laboratory Ltd.)
-
MRX PT DOAC – a New Way to Measure the Effect of DOACs (Nordic Biomarker)
-
Rapid Reversal of DOACs: Current and Future Perspectives (Norgine)
-
Managing the Challenges of IVDR Transition Together (Siemens Healthineers)
Sunday, July 10, 13:15 – 14:30 Supported Symposia
-
Make the Right Call: Protecting Vulnerable Patients With Venous Thrombosis (Bayer AG)
-
Advancing Care for Haemophilia: How Do We Keep Up With the Times? (CSL Behring)
-
Evidence-Based Responses to Key Clinical Questions Relating to Hemophilia A Management (F. Hoffmann-La Roche Ltd)
-
COVID-19 Coagulopathy and Long COVID: Haemostatic Changes and Implications for Diagnosis and Treatment (Haemonetics Corporation)
-
Health Equity for Haemophilia Patients with Inhibitors: Can We Do More? (LFB)
-
Mind the Gap: The Journey to Address Unmet Needs Across all Haemophilia Indications (Novo Nordisk)
-
Immune Thrombocytopenia: Disease Burden and Treatment Challenges in the COVID-19 Era (Sanofi)
Monday, July 11, 07:00 – 07:45 Supported Symposium
-
Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (CAT) (Anthos Therapeutics)
Monday, July 11, 07:00 – 07:45 Presentation Theater
-
Implementing a Multimodal Approach to VTE Prevention Today (Cardinal Health)
Monday, July 11, 12:15 – 13:00 Presentation Theaters
-
Advances in von Willebrand Disease (vWD): A View From the Clinic (CSL Behring)
-
Driving Change: Improving Diagnosis of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls (Novo Nordisk Healthcare AG)
-
Lupus Anticoagulant Diagnostics: Why you Need More Snakes (Technoclone)
Monday, July 11, 13:15 – 14:30 Presentation Theaters
-
Roundtable Discussion: Clinical Challenges in Patients with Venous Thromboembolism – Following the Data (BMS/Pfizer)
-
Factors to Consider: Expert Perspectives on Haemophilia A (Sobi Sanofi)
-
A Chronic Disease Burden: Exploring the Acute and Long-term Manifestations of TTP on Patients’ Lives (Takeda Pharmaceutical Company Limited)
Tuesday, July 12, 12:15 – 13:00 Presentation Theaters
-
Breakthrough Applications for Thrombin Generation (Diagnostica Stago)
-
Current Advances in Deficient Factors, D-Dimer and Thrombophilia Testing (HORIBA Medical)
-
Insights From Real World Practice to Support Haemophilia B Patients (Sobi Sanofi)
Tuesday, July 12, 13:15 – 14:30 Supported Symposia
-
Strategies for Assessing and Managing DOAC-Related Bleeding (AstraZeneca)
-
Focus on Females: Patient Experience & Novel Treatment Strategies in Bleeding Disorders (Octapharma AG)
-
Advances in Diagnosis and Management of Bleeding Disorders (Roche)
-
Medically-Ill Patients: VTE Prophylaxis in Hospital and Beyond (Sanofi)
-
Towards Health Equity: Upcoming Standards in Haemophilia Management (Sanofi)
-
Looking Towards the Future: Individualizing Treatment for Patients with Congenital and Acquired Hemophilia A (Takeda Pharmaceutical Company Limited)
For more information on these sessions, visit the online program here.